GlaxoSmithKline announced that the Food and Drug Administration approved its supplemental new drug application for Promacta (eltrombopag), a once-daily medication for patients with severe aplastic anaemia who have had an insufficient response to immunosuppressive therapy.
Fera Pharmaceuticals on Monday announced that it was selected by Pragma Pharmaceuticals to launch amoxicillin extended-release tablets
DSN presents a preview of some of the hottest pharmacy and technology products that will appear on the show floor at NACDS Total Store Expo.
Pharmacy health information technology has come a long way in the past five years, but there is still a significant amount of opportunity for pharmacy operations to plug into the HIT network — opportunities that will augment pharmacy’s value to the healthcare system in improving adherence and reducing abandonment.
With diabetes and other diseases at epidemic levels, the need for more pharmacies to step up and offer accessible, convenient patient screening for a variety of serious and even life-threatening conditions is clear, a panel of pharmacists asserted at Monday’s “Convenient Care — Point of Care Testing in the Pharmacy” session.
Emdeon on Monday announced the launch of Emdeon Easy Save for retail pharmacies. The program gives access to some of the largest co-pay assistance programs available, while also encouraging retail pharmacies to offer co-pay coupon programs to customers when they need it, according to the company.
Nipro Diagnostics announced that the Food and Drug Administration approved its True Metrix self-monitoring blood-glucose system, as well as the True Metrix Pro professional monitoring blood-glucose system.
Pharmaceutical company Iroko announced today that a new version its anti-inflammatory drug Zorvolex had been approved by the Food and Drug Administration.
ViiV Healthcare announced that the Food and Drug Administration has approved Triumeq (abacavir 600 mg, dolutegravir 50 mg and lamivudine 300 mg) tablets for the treatment of HIV-1 infection.
Biotech company Roche will be acquiring research and pharmaceutical company InterMune for $8.3 billion, it announced over the weekend.